VEGF: Novus Biologicals

DVE00

Human VEGF Quantikine ELISA Kit

(705 Publications)

1 Kit

DVE00

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

Conjugate	Catalog #	Availability	Size	Price
HRP	SVE00
HRP	PDVE00

compare

(select up to 3 products from this page to compare)

293-VE

Recombinant Human VEGF 165 Protein

(472 Publications)

10 μg

293-VE

As an alternative, please consider our next generation Recombinant Human VEGF 165 (Catalog # BT-VEGF). It has equivalent bioactivity to Recombinant Human VEGF 165 (Catalog # 293-VE). It combines R&D Systems quality with scalability that allows for a solid supply chain. Both Recombinant Human VEGF 165 proteins are measured in a cell proliferation assay using HUVEChuman umbilical vein endothelial cells.

1 μg/lane of Recombinant Human VEGF<SUB>165</SUB>was resolved by SDS-PAGE with silver staining, under reducing (R) and non-reducing (NR) conditions, showing major bands at 20-22 kDa and 39-42 kDa, respectively. Multiple bands in gel are due to glycosylation.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	293-VE-001MG/CF
Carrier Free	293-VE-010/CF
Carrier Free	293-VE-050/CF
Carrier Free	293-VE-500/CF

compare

(select up to 3 products from this page to compare)

MMV00

Mouse VEGF Quantikine ELISA Kit, 2 Plate

(237 Publications)

1 Kit (1 Plate)

MMV00

Increased production of proinflammatory cytokines and VEGF in the plasma and chondrocytes in high fat diet (HFD)-feeding mice.(a~d) levels of plasma IL-6 (a), TNF-alpha (b), IL-1 beta (c) and VEGF (d) in the C57BL/6 male mice fed with a normal diet (ND) or HFD for 8 weeks. (n = 5, **P < 0.01). (e~h) Relative mRNA expression of IL-6 (e), TNF-alpha (f), IL-1 beta (g) and VEGF (h) in the chondrocytes isolated from the 8-week ND or HFD-feeding mice. (n = 5, **P < 0.01). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26271607), licensed under a CC-BY license. Not internally tested by R&D Systems.

$HFD-induced plasma saturated free fatty acid (FFA) and lactate trigger production of proinflammatory cytokines and VEGF in mouse chondrocytes.(a~d) Relative mRNA levels of IL-6 (a), TNF-alpha (b), IL-1 beta (c) and VEGF (d) in the mouse primary chondrocytes treated with full or fractionated (>3 KD or <3 KD) serum from the 8-week ND or HFD-feeding mice. (n = 3, *P < 0.05, **P < 0.01 and ***P < 0.005). (e~h) Relative mRNA levels of IL-6 (e), TNF-alpha (f), IL-1 beta (g) and VEGF (h) in the mouse primary chondrocytes treated with BSA (5%) or BSA-linked FFA (18:0, 200 μM) for 24 h. (n = 3, *P < 0.05 and **P < 0.01). (i~l) Relative mRNA expression of IL-6 (i), TNF-alpha (j), IL-1 beta (k) and VEGF (l) in the mouse primary chondrocytes treated with lactate (25 mM) or vehicle control for 24 h. (n = 3, *P < 0.05 and **P < 0.01). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26271607), licensed under a CC-BY license. Not internally tested by R&D Systems.$

FFA and lactate enhance production of proinflammatory cytokines and VEGF via HIF1 alpha in mouse chondrocytes.(a) Immunoblotting assay of HIF1 alpha in primary chondrocytes transfected with a scramble siRNA (siNC, 20 nM), a mouse HIF1 alpha specific siRNA1 (siH-1, 20 nM) or siRNA2 (siH-2, 20 nM) for 36 h. (b~e) Relative mRNA levels of IL-6 (b), TNF-alpha (c), IL-1 beta (d) and VEGF (e) in the mouse primary chondrocytes transfected with siNC (20 nM), siH-1 (20 nM) or siH-2 (20 nM)for 12 h plus additional treatment with BSA (5%) or FFA (200 μM) for 24 h. Values not sharing a common superscript letter differ significantly. (n = 3, P < 0.05). (f~i) Relative mRNA levels of IL-6 (f), TNF-alpha (g), IL-1 beta (h) and VEGF (i) in the mouse primary chondrocytes transfected with siNC (20 nM), siH-1 (20 nM) or siH-2 (20 nM) for 12 h plus additional treatment with lactate (25 mM) or vehicle control for 24 h. Values not sharing a common superscript letter differ significantly. (n = 3, P < 0.05). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/26271607), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

Applications:

Conjugate	Catalog #	Availability	Size	Price
HRP	PMMV00
HRP	SMMV00

compare

(select up to 3 products from this page to compare)

DY293B

Human VEGF DuoSet ELISA, 15 Plate

(209 Publications)

1 Kit (for 5 Plates)

DY293B

Effects of cell stress on VEGF-A and HIF1 alpha expression in Müller cells and Y79 photoreceptors. (A) VEGF-A was measured by ELISA using conditioned media collected from MIO-M1 and Y79 cells, n = 4–5/group in Müller cells and n = 8/group in Y79 photoreceptors, ** p < 0.01; (B) Western blots for HIF1 alpha using cellular proteins, n = 4/group, ** p < 0.01. For MIO-M1 Müller cells: Grey bars: 5 mM glucose. Black bars: 25 mM glucose. For Y79 photoreceptors: Grey bars: 11 mM glucose. Black bars: 25 mM glucose. NS, not significant; LG, low glucose; HG, high glucose. Image collected and cropped by CiteAb from the following open publication (//www.mdpi.com/1422-0067/18/3/533), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

compare

(select up to 3 products from this page to compare)

AF-493-NA

VEGF Antibody [Unconjugated] - 164

(2 Reviews)

(145 Publications)

100 μg

AF-493-NA

293-VE), Recombinant Mouse VEGF₁₆₄(Catalog # 493-MV), Recombinant Mouse VEGF₁₂₀(Catalog # 494-VE), Recombinant Mouse VEGF-B₁₆₇(Catalog # 2595-VE), Recombinant Mouse VEGF-B 186 (Catalog # 767-VE), Recombinant Mouse VEGF₁₈₈(Catalog # 7916-MV), and Recombinant Rat VEGF₁₆₄(Catalog # 564-RV). PVDF Membrane was probed with 0.1 µg/mL of Goat Anti-Mouse VEGF₁₆₄Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for VEGF at approximately 18-27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." class="big_lightbox">

Western blot shows 25 ng of Recombinant Human VEGF<sub>165</sub>(Catalog # <a class=

293-VE), Recombinant Mouse VEGF₁₆₄(Catalog # 493-MV), Recombinant Mouse VEGF₁₂₀(Catalog # 494-VE), Recombinant Mouse VEGF-B₁₆₇(Catalog # 2595-VE), Recombinant Mouse VEGF-B 186 (Catalog # 767-VE), Recombinant Mouse VEGF₁₈₈(Catalog # 7916-MV), and Recombinant Rat VEGF₁₆₄(Catalog # 564-RV). PVDF Membrane was probed with 0.1 µg/mL of Goat Anti-Mouse VEGF₁₆₄Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for VEGF at approximately 18-27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." alt="Western blot shows 25 ng of Recombinant Human VEGF₁₆₅(Catalog # 293-VE), Recombinant Mouse VEGF₁₆₄(Catalog # 493-MV), Recombinant Mouse VEGF₁₂₀(Catalog # 494-VE), Recombinant Mouse VEGF-B₁₆₇(Catalog # 2595-VE), Recombinant Mouse VEGF-B 186 (Catalog # 767-VE), Recombinant Mouse VEGF₁₈₈(Catalog # 7916-MV), and Recombinant Rat VEGF₁₆₄(Catalog # 564-RV). PVDF Membrane was probed with 0.1 µg/mL of Goat Anti-Mouse VEGF₁₆₄Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for VEGF at approximately 18-27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." class="big_thumb" />

Fluorescent IHC Staining of Frozen Tissue Sections." class="big_lightbox">

Vascular Endothelial Growth Factor 164 (VEGF<sub>164</sub>) was detected in perfusion fixed frozen sections of mouse kidney using Goat Anti-Mouse VEGF<sub>164</sub>Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained (red) and counterstained (green). View our protocol for <a class=

Fluorescent IHC Staining of Frozen Tissue Sections." class="big_thumb" />

493-MV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line), as measured by Resazurin (AR002). Proliferation elicited by Recombinant Mouse VEGF₁₆₄ (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse VEGF₁₆₄ Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA). The ND₅₀ is typically <0.15 µg/mL." class="big_lightbox">

Recombinant Mouse VEGF<sub>164</sub> (Catalog # <a class=

493-MV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line), as measured by Resazurin (AR002). Proliferation elicited by Recombinant Mouse VEGF₁₆₄ (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse VEGF₁₆₄ Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA). The ND₅₀ is typically <0.15 µg/mL." class="big_thumb" />

Altered expression of VEGF-A following myeloid-specific ablation of NG2. Double immunostaining for VEGF-A (red) and CD31 (green) was used to quantify and localize VEGF-A expression in tumors from control (A–C) and Mac-NG2ko tumors (D–F). Overall expression of VEGF-A increases 3-fold in Mac-NG2ko tumors (G), consistent with the increased HIF-1 alpha expression seen in Fig. 5I. However, VEGF-A in control tumors is highly localized to blood vessels, while vascular VEGF-A in Mac-NG2ko tumors is reduced 3-fold (H). Instead, non-vascular VEGF-A in Mac-NG2ko tumors is increased by a factor of 5 (I). Scale bars = 60 μm. *p < 0.01 compared to controls. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26137396), licensed under a CC-BY license. Not internally tested by R&D Systems.

493-MV) was serially diluted and captured by Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

Recombinant Mouse VEGF 164 (Catalog # <a class=

493-MV) was serially diluted and captured by Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

493-MV) was serially diluted and captured by Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

493-MV) was serially diluted and captured by Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-493-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

, , ,

Applications: , , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	AF-493-NAU-100UG
Alexa Fluor 405	AF-493-NAV-100UG
Alexa Fluor 488	AF-493-NAG-100UG
Alexa Fluor 532	AF-493-NAX-100UG
Alexa Fluor 594	AF-493-NAT-100UG
Alexa Fluor 647	AF-493-NAR-100UG
Alexa Fluor 700	AF-493-NAN-100UG
Alexa Fluor 750	AF-493-NAS-100UG
Alexa Fluor Plus 405	AF-493-NAAFP405
Alexa Fluor Plus 488	AF-493-NAAFP488
Alexa Fluor Plus 555	AF-493-NAAFP555
Alexa Fluor Plus 594	AF-493-NAAFP594
Alexa Fluor Plus 647	AF-493-NAAFP647
Alexa Fluor Plus 680	AF-493-NAAFP680
Allophycocyanin	AF-493-NAA
Biotin	BAF493
CoraFluor 1	AF-493-NACL1
DyLight 350	AF-493-NAD
DyLight 405	AF-493-NAE
DyLight 488	AF-493-NAK
DyLight 550	AF-493-NAL
DyLight 594	AF-493-NAM
DyLight 650	AF-493-NAW
DyLight 680	AF-493-NAY
DyLight 755	AF-493-NAZ
FITC	AF-493-NAF
HRP	AF-493-NAH
Janelia Fluor 525	AF-493-NAJF525
Janelia Fluor 549	AF-493-NAI
Janelia Fluor 646	AF-493-NAJ
Janelia Fluor 669	AF-493-NAJF669
PE	AF-493-NAP
PerCP	AF-493-NAC
mFluor Violet 450 SE	AF-493-NAMFV450
mFluor Violet 500 SE	AF-493-NAMFV500
mFluor Violet 610 SE	AF-493-NAMFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF-493-SP

compare

(select up to 3 products from this page to compare)

MAB293

VEGF Antibody (26503) [Unconjugated]

(124 Publications)

100 μg

MAB293

293-VE), Recombinant Human VEGF₁₁₁ (5336-VE), Recombinant Human VEGF₁₂₁, aa 207-327 (4644-VS), Recombinant Human VEGF₁₄₅ (aa 27-171) (7626-VE), Recombinant Human VEGF₁₆₂ (2347-VE), Recombinant Human VEGF_165b (3045-VE), Recombinant Human VEGF₁₈₉ (aa 27-215) (8147-VE), Recombinant Human VEGF₁₆₅ Extended Isoform (9018-VE), Recombinant Human VEGF-B₁₆₇ (751-VE), Recombinant Mouse VEGF₁₆₄ (493-MV), and Recombinant Rat VEGF₁₆₄ (564-RV). PVDF Membrane was probed with 0.1 µg/mL of Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF007). A specific band was detected for VEGF at approximately 15-25 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." class="big_lightbox">

Western blot shows 25 ng of Recombinant Human VEGF<sub>165</sub> (<a class=

293-VE), Recombinant Human VEGF₁₁₁ (5336-VE), Recombinant Human VEGF₁₂₁, aa 207-327 (4644-VS), Recombinant Human VEGF₁₄₅ (aa 27-171) (7626-VE), Recombinant Human VEGF₁₆₂ (2347-VE), Recombinant Human VEGF_165b (3045-VE), Recombinant Human VEGF₁₈₉ (aa 27-215) (8147-VE), Recombinant Human VEGF₁₆₅ Extended Isoform (9018-VE), Recombinant Human VEGF-B₁₆₇ (751-VE), Recombinant Mouse VEGF₁₆₄ (493-MV), and Recombinant Rat VEGF₁₆₄ (564-RV). PVDF Membrane was probed with 0.1 µg/mL of Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF007). A specific band was detected for VEGF at approximately 15-25 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." alt="Western blot shows 25 ng of Recombinant Human VEGF₁₆₅ (293-VE), Recombinant Human VEGF₁₁₁ (5336-VE), Recombinant Human VEGF₁₂₁, aa 207-327 (4644-VS), Recombinant Human VEGF₁₄₅ (aa 27-171) (7626-VE), Recombinant Human VEGF₁₆₂ (2347-VE), Recombinant Human VEGF_165b (3045-VE), Recombinant Human VEGF₁₈₉ (aa 27-215) (8147-VE), Recombinant Human VEGF₁₆₅ Extended Isoform (9018-VE), Recombinant Human VEGF-B₁₆₇ (751-VE), Recombinant Mouse VEGF₁₆₄ (493-MV), and Recombinant Rat VEGF₁₆₄ (564-RV). PVDF Membrane was probed with 0.1 µg/mL of Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF007). A specific band was detected for VEGF at approximately 15-25 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." class="big_thumb" />

293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (AR002). Proliferation elicited by Recombinant Human VEGF₁₆₅ (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293). The ND₅₀ is typically 10-60 ng/mL." class="big_lightbox">

Recombinant Human VEGF<sub>165</sub> (<a class=

293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (AR002). Proliferation elicited by Recombinant Human VEGF₁₆₅ (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293). The ND₅₀ is typically 10-60 ng/mL." class="big_thumb" />

<b>Biological Strategies Validation. </b>Protein levels of VEGF (A), KDR (VEGF receptor 2, B), Angiopoietin 1 (C) and Tie2 (D) from retinal endothelial cells cultured in normoxia or hypoxia only and cells in each condition treated with Compound 49b. Hypoxia increased protein levels of all proteins, which were significantly reduced after treatment with Compound 49b. Data is mean ± SEM. *P<0.05 vs. normoxia. #P<0.05 vs. hypoxia. N = 4. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27439004), licensed under a CC-BY license. Not internally tested by R&D Systems.

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

Recombinant Human VEGF 165 (Catalog # <a class=

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

Reactivity:

Hu, Pm

Species Glossary

Reactivity: Hu, Pm

Applications:

, ,

Applications: , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Allophycocyanin	FAB293A
Biotin	FAB293B
CoraFluor 1	FAB293CL1
DyLight 350	FAB293D
DyLight 405	FAB293E
DyLight 488	FAB293K
DyLight 550	FAB293L
DyLight 594	FAB293M
DyLight 650	FAB293W
DyLight 680	FAB293Y
DyLight 755	FAB293Z
FITC	FAB293F
HRP	FAB293H
Janelia Fluor 525	FAB293JF525
Janelia Fluor 549	FAB293I
Janelia Fluor 646	FAB293J
Janelia Fluor 669	FAB293JF669
PE	FAB293P
PerCP	FAB293C
mFluor Violet 450 SE	FAB293MFV450
mFluor Violet 500 SE	FAB293MFV500
mFluor Violet 610 SE	FAB293MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB293-SP
Carrier Free	MAB293-500

compare

(select up to 3 products from this page to compare)

NB100-664

VEGF Antibody (VG1) - BSA Free

(1 Review)

(100 Publications)

0.1 mg

NB100-664

U87 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-664 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

VEGF-Antibody-VG1-BSA-Free-Immunohistochemistry-NB100-664-img0015.jpg

An intracellular stain was performed on U-937 cells with NB100-664 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

VEGF-Antibody-VG1-BSA-Free-Western-Blot-NB100-664-img0019.jpg

HUVEC and 293T cells transfected with a plasmid expressing human VEGF165 at 1:1000. Image provided by verified customer review.

FFPE human angiosarcoma tissue section using VEGF antibody (clone VG1). The endothelial cells of the blood vessels and most of the cancer cells showed strong positivity for VEGF protein.

Analysis of PerCP conjugate of NB100-664. An intracellular stain was performed on HUVEC cells with VEGF (VG1) antibody NB100-664PCP (blue) and a matched isotype control NBP2-27287PCP (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to PerCP.

An intracellular stain was performed on U-937 cells with NB100-664F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.

Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib reduced TNBC cell migration & targeted p-STAT3/VEGF-A signaling.(A) Chemical structure of regorafenib. (B,C), Transwell assay (B) & wound-healing assay (C) were performed in TNBC cell lines after regorafenib treatment for 24 h. *p < 0.05, **p < 0.01. (D) dose-dependent effects of regorafenib on p-STAT3 & VEGF-A proteins were analyzed by western blot. (E) Dose-dependent effects of regorafenib on VEGF-A mRNA were analyzed by qPCR. TNBC cells were exposed to the indicated doses for 24 hours. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - SC-78, a derivative of regorafenib, exhibited more potent anti-migratory effects than regorafenib.(A) Chemical structure of SC-78. (B) The protein levels of p-VEGFR2, VEGFR2, p-PDGFR, & PDGFR in EAhy926 treated with various doses of regorafenib or SC-78 were determined by western blot. (C,D), The effect of SC-78 on migration of human TNBC cells was analyzed by Transwell migration assay (C) & wound-healing assay (D). *p < 0.05, **p < 0.01. (E) Human TNBC cells were treated with SC-78 dose dependently for 24 h, & the cell lysates were subjected to western blot assay. (F) MDA-MB-231 cells were transfected with vector control or VEGF-A overexpression plasmid (left), STAT3 overexpression plasmid (middle), scramble or SHP-1 siRNA (right), respectively. After 48 h transfection, cells were treated with SC-78 (2.5 μM) for 24 h & subjected to western blot assay or cells analyzed by Transwell migration assay. *p < 0.05, **p < 0.01. (G) SHP-1 activity assay was performed in MDA-MB-231 & MDA-MB-468 cells treated with SC-78 dose dependently. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Anti-tumor activity of regorafenib & SC-78 in a murine TNBC metastasis model.(A) Nude mice were subcutaneously injected with MDA-MB-468 cells (2 × 106). Mice were treated with vehicle, bevacizumab (125 μg/100 μl, twice a week, IP), regorafenib, or SC-78 (10 mg/kg, everyday, oral) for 43 days (n = 6), & the tumor size (left, bottom) was measured. In vivo protein levels were analyzed (Middle, top). Middle, bottom, the in vivo SHP-1 activity. Right, Representative images of IHC staining (100 × ). *p < 0.05, **p < 0.01. (B) Luciferase-expressing MDA-MB-231 (1 × 106) cells were injected orthotopically into the mammary fat pad of the mice. After two weeks, mice received regorafenib & SC-78, or vehicle orally at 10 mg/kg/every day (n = 5). Tumor growth was monitored by IVIS imaging system at the indicated times. Left, top, visualized by IVIS analysis. Left, bottom, quantification analysis from the IVIS total flux. Right, Representative images of IHC staining (100×). *p < 0.05, **p < 0.01. (C) In vivo bioluminescence images of nude mice injected i.v. with MDA-MB-231/Luc2 cells (1 × 106). After bioluminescence was observed, mice received vehicle or SC-78 orally at 10 mg/kg/every day. left, visualized by IVIS analysis. Right, Kaplan–Meier plot showing animal survival after treatment with vehicle or SC-78 (n = 8). The survival endpoint was set at 64 days after drug administration. (D) Schematic displays the drug mechanism of regorafenib & SC-78 on VEGF-A autocrine & paracrine inhibition & cell migration. SC-78 suppressed cancer metastasis dominantly through SHP-1 dependent-STAT3 dephosphorylation. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Notch-1 is identified as an intermediate molecule in the miR-1956-VEGF axis. (A) Notch-1 is a target gene for miR-1956. The sequence of miR-1956, the potential binding site at the 3' UTR of Notch-1 mRNA, & the nucleotides mutated in the Notch-1-3' UTR mutant are shown. HEK293 cells were transiently cotransfected with miR-1956 mimic or NC using luciferase reporter vectors. The luciferase activity was normalized to the activity of Renilla luciferase. Data are shown as mean ± SD from three independent experiments. *, significantly different from NC; **, p < 0.01. After transfection with 50 nmol/L of miR-1956 mimic for 3 days, the mRNA level of Notch-1 was determined using qRT-PCR (B), & the protein expression of Notch-1 was measured using western blotting (C). For B, data are shown as mean ± SD from three independent experiments. *, significantly different from control; **, p < 0.01. For C, representative images of two independent experiments are shown. Data are shown as mean ± SD. *, significantly different from control; **, p < 0.01. ADMSCs were transfected with 2.5 μg Notch-1 plasmid & 50 nmol/L miR-1956 mimic or 100 nmol/L miR-1956 inhibitor for 3 days, the intracellular expression of Notch-1 (D) & VEGF (E) was detected by western blotting. For D & E, representative images of four independent experiments are shown. Data are shown as mean ± SD. *, significantly different from the control group transfected with control plasmid & NC mimic or inhibitor; *, p < 0.01; **, p < 0.01. #, significantly different from the group transfected with Notch-1 plasmid & NC mimic or inhibitor; #, p < 0.05. One-way ANOVA followed by Tukey's post-test was performed (A-E). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31938051), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - SHP-1 is negatively associated with p-STAT3/VEGF-A signaling & metastasis in TNBC cells & clinical samples.(A) Protein expression pattern of SHP-1, p-STAT3, & VEGF-A in nine TNBC cell lines were analyzed by western blot. (B) The migration abilities of nine TNBC cell lines were analyzed by Transwell assay. DAPI stains the nuclei. BT-20 cells were used as a normalization control. (C) The correlation (linear regression model) of VEGF-A (top), p-STAT3 (middle), & SHP-1 (bottom) & migration ability in nine TNBC cell lines. (D) TNBC cells from representative two patients with SHP-1, p-STAT3, & VEGF-A staining. (200×) (E) Kaplan-Meier graph was prepared to compare DMFS (left) & DFS (right) in patients with high VEGF-A (H score > 160) or low VEGF-A (H score < = 160) levels for the indicated time of follow up. Chi-square test indicated a significant difference between VEGF-A high (N = 21) & low (N = 76) patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

VEGF expression in mouse liver tissues. Dilution: 2 ug/ml in 1X TBST. Image from a verified customer review.

Analysis of a FFPE tissue section of human liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.

Analysis of a FFPE tissue section of mouse liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.

HPG induces less VEGF production, less myofibroblast differentiation and lower macrophage activation. The expression of VEGF, alpha -SMA and MAC387 in the peritoneal tissue sections was examined using a routine immunohistochemical method. Data were a typical microscopic view of the peritoneal tissue sections in each group. a VEGF was detected using mouse monoclonal anti-VEGF antibody from Novus. Left graph a typical microscopic view, Dark brown stain VEGF-expressing cells (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 um. Right graph VEGF-expressing cells per 200 μm PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test. b alpha -SMA (a myofibroblast marker) was detected using mouse monoclonal anti-alpha -SMA antibody from Sigma-Aldrich. Left graph a typical microscopic view, Dark brown stain alpha -SMA-expressing cells or myofibroblasts (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 um. Right graph alpha -SMA-expressing cells per 200 μm PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test. c Macrophages were detected using mouse monoclonal anti-MAC387 antibody from Santa Cruz Biotech. Left graph a typical microscopic view, Dark brown stain MAC387-expressing cells or macrophages (pointed by red arrows), M muscle, black small bar 10 um. Right graph MAC387-expressing cells per 200 μm PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/27964722), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Comparison of Col I and VEGF expression. (A) Representative images of Col I and VEGF immunohistochemical staining (30× magnification). Col I was stained with a reddish color. The black arrows indicate the location of VEGF staining. (B) Quantification of Col I and VEGF expression by immunohistochemical staining (mean +/- SD). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37151660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Po, Ca

Species Glossary

Reactivity: Hu, Mu, Rt, Po, Ca

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-664AF350
Alexa Fluor 405	NB100-664AF405
Alexa Fluor 488	NB100-664AF488
Alexa Fluor 532	NB100-664AF532
Alexa Fluor 594	NB100-664AF594
Alexa Fluor 647	NB100-664AF647
Alexa Fluor 700	NB100-664AF700
Alexa Fluor 750	NB100-664AF750
Alexa Fluor Plus 405	NB100-664AFP405
Alexa Fluor Plus 488	NB100-664AFP488
Alexa Fluor Plus 555	NB100-664AFP555
Alexa Fluor Plus 594	NB100-664AFP594
Alexa Fluor Plus 647	NB100-664AFP647
Alexa Fluor Plus 680	NB100-664AFP680
Allophycocyanin	NB100-664APC
Biotin	NB100-664B
CoraFluor 1	NB100-664CL1
DyLight 350	NB100-664UV
DyLight 405	NB100-664V
DyLight 488	NB100-664G
DyLight 550	NB100-664R
DyLight 594	NB100-664DL594
DyLight 650	NB100-664C
DyLight 680	NB100-664FR
DyLight 755	NB100-664IR
FITC	NB100-664F
HRP	NB100-664H
Janelia Fluor 525	NB100-664JF525
Janelia Fluor 549	NB100-664JF549
Janelia Fluor 646	NB100-664JF646
Janelia Fluor 669	NB100-664JF669
PE	NB100-664PE
PerCP	NB100-664PCP
mFluor Violet 450 SE	NB100-664MFV450
mFluor Violet 500 SE	NB100-664MFV500
mFluor Violet 610 SE	NB100-664MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-664SS
Azide and BSA Free	NBP2-81007

compare

(select up to 3 products from this page to compare)

AF-293-NA

VEGF Antibody [Unconjugated] - 164

(2 Reviews)

(87 Publications)

100 μg

AF-293-NA

HAF017). A specific band was detected for VEGF at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox">

Western blot shows lysates of human lung tissue, human kidney tissue, and human liver tissue. PVDF membrane was probed with 5-10 µg/mL of Goat Anti-Human VEGF <sub>165</sub>Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (<a class=

HAF017). A specific band was detected for VEGF at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of human lung tissue, human kidney tissue, and human liver tissue. PVDF membrane was probed with 5-10 µg/mL of Goat Anti-Human VEGF ₁₆₅Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF017). A specific band was detected for VEGF at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

NL001) and counter-stained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells." class="big_lightbox">

VEGF was detected in immersion fixed human umbilical vein endothelial cells (HUVECs) using Goat Anti-Human VEGF<SUB>165</SUB> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; <a class=

NL001) and counter-stained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells." class="big_thumb" />

VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VEGF was detected in immersion fixed paraffin-embedded sections of human liver cancer tissue using Goat Anti-Human VEGF<sub>165</sub> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (<a class=

VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF₁₆₅ (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human VEGF₁₆₅ Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA). The ND₅₀ is typically 0.02‑0.12 µg/mL." class="big_lightbox">

293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF₁₆₅ (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human VEGF₁₆₅ Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA). The ND₅₀ is typically 0.02‑0.12 µg/mL." class="big_thumb" />

VEGF expression determined by Western blot and immunoprecipitation.A. Western blot using LiCor Odyssey to simultaneously image pan-VEGF and VEGF-A165b probed western blot. Two different podocyte samples, and a primary RPE sample were run on a gel and probed with antibodies to VEGF-A165b (mouse monoclonal anti-CTRSLTRKD, and 680nm-donkey anti-mouse, top image) and pan-VEGF (rabbit polyclonal anti-VEGF, and 800nm-donkey anti-rabbit, middle image). The bottom image is the pseudocoloured combined image (600nm green, 800nm red). Note the red VEGF165, but yellow VEGF-A165b. MWM = molecular weight marker. d = dimer, m = monomer. B. Protein extracted from human cell lines (adenoma and adenocarcinoma(AC)) subjected to immunoprecipitation (IP) for VEGF-A165b and immunoblotting (IB) for total VEGF-A. A clear strong band was seen in the IP for both cell types at ∼23kDa and ∼46kDa, consistent with the IP for recombinant human VEGF-A165b. A weaker band was seen in the input protein (not subjected to IP), and a second band slightly higher in the AC. A weak band at approximately 56kDa and 28kDa was seen in all lanes subjected to IP, including the VEGF-A165a band, but not seen in the recombinant human VEGF-A165b not subjected to IP, indicating that this is cross reactivity with the IgG. This band was clearly above the VEGF-A165b bands. C. Protein extracted from human cell lines (adenoma and adenocarcinoma(AC)) subjected to immunoprecipitation (IP) for VEGF-A and immunoblotting (IB) for VEGF-A165b. A clear strong band was seen in the IP for both cell types at ∼23kDa, the same size as recombinant human VEGF-A165b. In the input a band at ∼46Da was seen predominantly, for both cell types, labelled as VEGF-A165b dimers. D. Mouse tissues probed with VEGF-A165b antibody detect mouse IgG due to the secondary antibody. Top image, western blot of mouse tissues, recombinant mouse IgG or human VEGF-A165b or VEGF-A165b probed with mouse anti-CTRSLTRKD, and 680nm-donkey anti-mouse IgG. Bottom ima

Inhibitor of differentiation 4 (ID4) expression in breast cancer cells leads to the activation of an angiogenic programme in macrophages. a Expression matrix representing a panel of angiogenic factors evaluated using TaqMan Low-Density Arrays (TLDA) in macrophages obtained by 1,25-dihydroxyvitamin D3 (VitD3)-mediated differentiation of HL60 cells and subsequently cultured in RPMI medium or in conditioned media (CM) from control (EV) or ID4-overexpressing (ID4) MDA-MB-468 breast cancer cells. b Western blot showing ID4-HA overexpression in MDA-MB-468 cells. c Selected genes modulated in the arrays were evaluated by RT-qPCR in macrophages obtained from VitD3-mediated differentiation of U937 cells and subsequently cultivated in RPMI medium (CTR) or in CM from control (CM si-SCR) or ID4-depleted (CM si-ID4) MDA-MB-468 cells. d Western blot analysis showing the level of ID4 protein after transfection of the indicated small interfering RNAs (siRNAs) in MDA-MB-468 cells. e–g Western blot analysis of ephrin B2 (EphB2), granulin (GRN) and hypoxia-inducible factor (HIF)-1A proteins in differentiated U937 cells cultured in CM si-SCR or CM si-ID4 from MDA-MB-468 cells. h Immunofluorescence analysis of HIF-1A protein performed in differentiated U937 cells cultured in the presence of CM si-SCR or CM si-ID4 from MDA-MB-468 cells. i Western blotting showing the efficiency of vascular endothelial growth factor A (VEGFA) depletion by siRNA transfection in MDA-MB-468 cells used to prepare CM used in experiments shown in (j). j RT-qPCR analysis of the indicated messenger RNAs in U937 macrophages cultivated in the presence of CM from control (si-SCR) or VEGFA-depleted (si-VEGFA) MDA-MB-468 cells. k RT-qPCR analysis of the indicated genes in differentiated U937 cells cultivated in RPMI medium or in CM from MDA-MB-468 cells in the presence of VEGFA blocking antibody (Ab) or a control Ab. Specifically, VEGFA blocking Ab or control Ab were incubated with CM for 30 minutes at room temperatur

<b>Biological Strategies Validation. </b>Western blot analysis of the effects of RNA interference on VEGF expression in HTF cells. (a) Relative expression of VEGF in cells treated with shRNA-2 and shRNA-3; (b) protein expression levels in treated groups and naïve HTF controls. ∗∗∗p < 0.01. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28168047), licensed under a CC-BY license. Not internally tested by R&D Systems.

AF-293-NA) at 5ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to hepatocytes. " class="big_lightbox">

Formalin-fixed paraffin-embedded tissue sections of human liver were probed for VEGF mRNA (ACD RNAScope Probe, catalog #423168, Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using goat anti-human VEGF polyclonal antibody (R&D Systems catalog # <a class=

AF-293-NA) at 5ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to hepatocytes. " class="big_thumb" />

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

293-VE) was serially diluted and captured by Mouse Anti-Human/Primate VEGF Monoclonal Antibody (Catalog # MAB293) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human VEGF 165 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-293-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , , ,

Applications: , , , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	AF-293-NAU-100UG
Alexa Fluor 405	AF-293-NAV-100UG
Alexa Fluor 488	AF-293-NAG-100UG
Alexa Fluor 532	AF-293-NAX-100UG
Alexa Fluor 594	AF-293-NAT-100UG
Alexa Fluor 647	AF-293-NAR-100UG
Alexa Fluor 700	AF-293-NAN-100UG
Alexa Fluor 750	AF-293-NAS-100UG
Alexa Fluor Plus 405	AF-293-NAAFP405
Alexa Fluor Plus 488	AF-293-NAAFP488
Alexa Fluor Plus 555	AF-293-NAAFP555
Alexa Fluor Plus 594	AF-293-NAAFP594
Alexa Fluor Plus 647	AF-293-NAAFP647
Alexa Fluor Plus 680	AF-293-NAAFP680
Allophycocyanin	AF-293-NAA
Biotin	BAF293
CoraFluor 1	AF-293-NACL1
DyLight 350	AF-293-NAD
DyLight 405	AF-293-NAE
DyLight 488	AF-293-NAK
DyLight 550	AF-293-NAL
DyLight 594	AF-293-NAM
DyLight 650	AF-293-NAW
DyLight 680	AF-293-NAY
DyLight 755	AF-293-NAZ
FITC	AF-293-NAF
HRP	AF-293-NAH
Janelia Fluor 525	AF-293-NAJF525
Janelia Fluor 549	AF-293-NAI
Janelia Fluor 646	AF-293-NAJ
Janelia Fluor 669	AF-293-NAJF669
PE	AF-293-NAP
PerCP	AF-293-NAC
mFluor Violet 450 SE	AF-293-NAMFV450
mFluor Violet 500 SE	AF-293-NAMFV500
mFluor Violet 610 SE	AF-293-NAMFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF-293-SP

compare

(select up to 3 products from this page to compare)

493-MV

Recombinant Mouse VEGF 164 Protein

(98 Publications)

5 μg

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

Applications:

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	493-MV-005/CF
Carrier Free	493-MV-025/CF

compare

(select up to 3 products from this page to compare)

RRV00

Rat VEGF Quantikine ELISA Kit

(76 Publications)

1 Kit

RRV00

Reactivity:

Rt

Species Glossary

Reactivity: Rt

Applications:

Applications:

compare

(select up to 3 products from this page to compare)

DY493

Mouse VEGF DuoSet ELISA, 15 Plate

(69 Publications)

1 Kit (for 5 Plates)

DY493

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

Applications:

compare

(select up to 3 products from this page to compare)

AF564

VEGF Antibody [Unconjugated] - 164

(51 Publications)

100 μg

AF564

CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." class="big_lightbox">

VEGF<sub>164</sub>was detected in perfusion fixed frozen sections of rat kidney using 15 µg/mL Goat Anti-Rat VEGF<sub>164</sub>Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # <a class=

CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." alt="VEGF₁₆₄was detected in perfusion fixed frozen sections of rat kidney using 15 µg/mL Goat Anti-Rat VEGF₁₆₄Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." class="big_thumb" />

564-RV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Rat VEGF₁₆₄(20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564). The ND₅₀ is typically 0.2-0.6 µg/mL." class="big_lightbox">

Recombinant Rat VEGF<sub>164</sub>(Catalog # <a class=

564-RV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Rat VEGF₁₆₄(20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564). The ND₅₀ is typically 0.2-0.6 µg/mL." class="big_thumb" />

564-RV), Recombinant Human VEGF 165 (Catalog # 293-VE) and Recombinant Mouse VEGF 164 (Catalog # 493-MV). PVDF Membrane was probed with 0.1 µg/mL of Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for VEGF at approximately 20-25 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.This antibody does not detect natural VEGF in lysates from cell lines or tissues." class="big_lightbox">

Western blot shows 25 ng of Recombinant Rat VEGF 164 (Catalog # <a class=

564-RV), Recombinant Human VEGF 165 (Catalog # 293-VE) and Recombinant Mouse VEGF 164 (Catalog # 493-MV). PVDF Membrane was probed with 0.1 µg/mL of Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for VEGF at approximately 20-25 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.This antibody does not detect natural VEGF in lysates from cell lines or tissues." class="big_thumb" />

Expression of proteins relevant to kidney regeneration in female MWF rats.Immunohistochemical staining of VEGF in female animals receiving saline or MET transplant, after 6 weeks. Scale bars = 50 μm. Representative immunofluorescence staining (red) of FGF2, HGF, IGF-1 and Pax-2 in female rats receiving saline or MET, on renal tissues labeled with WGA-lectin (green) and DAPI (blue). Scale bars = 50 μm, = 25 μm (for FGF2 and IGF-1). Semiquantitative analysis of immunohistochemical stainings of VEGF, FGF2, HGF, IGF-1 and Pax-2 in female MWF rats receiving saline or MET. Data are expressed as mean ± SE (n = 3/group). Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0120235), licensed under a CC-BY license. Not internally tested by R&D Systems.

<b>Biological Strategies Validation. </b>Depletion of BAMs attenuates ischemia-induced pial and cortical vascular permeability. BAMs were depleted by i.c.v. administration of clodronate liposomes (CL) 4 days prior to ischemia. For treatment control, rats received vehicle liposomes (V). a) Vegfa mRNA was studied in cortical and subcortical regions of the ipsilateral (ipsi, ischemic) and the contralateral (contra) brain hemispheres. Ischemia-induced expression of Vegfa mRNA at 24 h is attenuated in the cortex of the CL rats versus the V rats (n = 6 per group) (Mann Whitney test, p = 0.041). b) Western blotting of cortical and subcortical brain tissue (ipsilateral) 24 h post-ischemia shows the VEGF164 isoform of VEGF-A detected as two bands corresponding to the homodimeric and monomeric forms at approximately 54 kDa and 24 kDa. Quantification of signal intensity of the 54-kDa band shows reduced expression in the cortex of rats receiving CL vs. rats receiving V (n = 6 per group) (Mann-Whitney test, **p = 0.002). c) Ischemia increases the permeability of pial vessels (arrows), as assessed by Evans blue extravasation 24 h post-ischemia, and BAM depletion attenuates the effect. Images of one representative coronal brain section per rat of each treatment group show Evans blue extravasation in the ipsilateral hemisphere. Rats receiving clodronate show negligible Evans blue in the cortex (arrows in the schematic representation at the right hand side). The volume of tissue showing Evans blue extravasation is reduced in the cortex, but not in subcortical zones, of the CL group (n = 8) versus the V group (n = 7) (Mann-Whitney test, *p = 0.014). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30092836), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of mRNAs and proteins relevant to kidney regeneration in male MWF rats.(A) Real Time RT-PCR analysis of VEGF, FGF2, HGF, IGF-1 and Pax-2 in whole host renal tissues of male MWF rats receiving saline or metanephroi (MET) (in adjacent area), 6 weeks after transplantation. Data are expressed as mean ± SE; *P < 0.05, **P < 0.01 vs saline (n = 4 rats/group, VEGF n = 6 rats/group). (B) Immunohistochemical staining of VEGF (arrows) in male animals receiving saline or MET transplant, after 6 weeks. Scale bars = 50 μm. Representative immunofluorescence stainings (red) of FGF2, HGF, IGF-1 and Pax-2 in rats receiving saline or MET, on renal tissues labeled with WGA-lectin (green) and DAPI (blue). Scale bars = 50 μm, = 25 μm (for FGF2 and IGF-1). Semiquantitative analysis of immunohistochemical staining of VEGF, FGF2, HGF, IGF-1 and Pax-2 in male MWF rats receiving saline or MET. Data are expressed as mean ± SE; *P < 0.05, **P < 0.01 vs saline (n = 3/group). Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0120235), licensed under a CC-BY license. Not internally tested by R&D Systems.

Effect of fibroblasts transplanted under the kidney capsule of male MWF rats.(A) Histological appearance of renal tissue from male MWF rat transplanted with fibroblasts in adjacent (left, arrow) or distant (right) area. Scale bars = 200 μm. (B) Quantification of endothelium volume density (Vv), peritubular capillary length density (Jv), nitrotyrosine (NT)-positive tubuli, TUNEL-positive cells and Ki-67-positive cells, in renal tissues of MWF rats receiving fibroblasts or saline. Data are expressed as mean ± SE (n = 3 rats/group). (C) Representative immunohistochemical images of SMP30 (green), NCAM (red), VEGF (brown signal), FGF2 (red), HGF (red), IGF-1 (red) and Pax-2 (red) in male rats with fibroblast transplant. Sections are co-stained with rhodamine-LCA (in SMP30 panel, red) or with FITC-WGA lectin (in panels showing NCAM, FGF2, HGF, IGF-1, Pax2, green) and DAPI (blue). Scale bars = 50 μm. Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0120235), licensed under a CC-BY license. Not internally tested by R&D Systems.

564-RV) was serially diluted and captured by Mouse Anti-Rat VEGF 164 Monoclonal Antibody (Catalog # MAB564) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox">

Recombinant Rat VEGF 164 (Catalog # <a class=

564-RV) was serially diluted and captured by Mouse Anti-Rat VEGF 164 Monoclonal Antibody (Catalog # MAB564) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Rat VEGF 164 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF564) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

Reactivity:

Rt

Species Glossary

Reactivity: Rt

Applications:

, ,

Applications: , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	AF564U-100UG
Alexa Fluor 405	AF564V-100UG
Alexa Fluor 488	AF564G-100UG
Alexa Fluor 532	AF564X-100UG
Alexa Fluor 594	AF564T-100UG
Alexa Fluor 647	AF564R-100UG
Alexa Fluor 700	AF564N-100UG
Alexa Fluor 750	AF564S-100UG
Alexa Fluor Plus 405	AF564AFP405-100UG
Alexa Fluor Plus 488	AF564AFP488-100UG
Alexa Fluor Plus 555	AF564AFP555-100UG
Alexa Fluor Plus 594	AF564AFP594-100UG
Alexa Fluor Plus 647	AF564AFP647-100UG
Alexa Fluor Plus 680	AF564AFP680-100UG
Allophycocyanin	AF564A
Biotin	BAF564
CoraFluor 1	AF564CL1
DyLight 350	AF564D
DyLight 405	AF564E
DyLight 488	AF564K
DyLight 550	AF564L
DyLight 594	AF564M
DyLight 650	AF564W
DyLight 680	AF564Y
DyLight 755	AF564Z
FITC	AF564F
HRP	AF564H
Janelia Fluor 525	AF564JF525
Janelia Fluor 549	AF564I
Janelia Fluor 646	AF564J
Janelia Fluor 669	AF564JF669
PE	AF564P
PerCP	AF564C
mFluor Violet 450 SE	AF564MFV450
mFluor Violet 500 SE	AF564MFV500
mFluor Violet 610 SE	AF564MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF564-SP

compare

(select up to 3 products from this page to compare)

At	=	A. thaliana	SyHa	=	Golden Syrian Hamster
All	=	All Species	Ha	=	Hamster
An	=	Animal	Hu	=	Human
ArHa	=	Armenian Hamster	I	=	Insect
Av	=	Avian	Ll	=	Llama
Bb	=	Baboon	Ma	=	Mammal
Ba	=	Bacteria	Mk	=	Monkey
Bv	=	Bovine	Mu	=	Mouse
Ca	=	Canine	Multi	=	Multi-species
Ce	=	C. Elegans	NA	=	Non-species specific
Ch	=	Chicken	Or	=	Orangutan
ChHa	=	Chinese Hamster	Pl	=	Plant
Cm	=	Cynomolgus Monkey	Pm	=	Primate
Do	=	Donkey	Po	=	Porcine
Dr	=	Drosophilia	Rb	=	Rabbit
Ec	=	E. Coli	Rt	=	Rat
Eq	=	Equine	RM	=	Rhesus Macaque
Fe	=	Feline	Sh	=	Sheep
Ft	=	Ferret	Vb	=	Vertebrate
Fi	=	Fish	Vi	=	Virus
Fu	=	Fungi	Xp	=	Xenopus
Ge	=	Gerbil	Ye	=	Yeast
GP	=	Guinea Pig	Ze	=	Zebrafish
Gt	=	Goat

Category

Protein/Target

Applications

Reactivity

Citation

Reviews

Host

Available Conjugates

Format

Modification

Clonality

Clone

Gene Symbol

Images Type

Isotype

Preservative

Protein Or Peptide

Research Areas

Has Sample Size

Promotional Item

Species Glossary

vegfa Products By Gene Name

Human VEGF Quantikine ELISA Kit

Recombinant Human VEGF 165 Protein

Mouse VEGF Quantikine ELISA Kit, 2 Plate

Human VEGF DuoSet ELISA, 15 Plate

VEGF Antibody [Unconjugated] - 164

VEGF Antibody (26503) [Unconjugated]

VEGF Antibody (VG1) - BSA Free

VEGF Antibody [Unconjugated] - 164

Recombinant Mouse VEGF 164 Protein

Rat VEGF Quantikine ELISA Kit

Mouse VEGF DuoSet ELISA, 15 Plate

VEGF Antibody [Unconjugated] - 164